<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/ms2025-541</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-9727</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>НЕРВНО-ПСИХИЧЕСКИЕ РАССТРОЙСТВА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>NEUROPSYCHIATRIC DISORDERS</subject></subj-group></article-categories><title-group><article-title>Пограничное расстройство личности в призме исследований и практическом преломлении: факты и клинический случай</article-title><trans-title-group xml:lang="en"><trans-title>Borderline personality disorder in the research prism and practical approach: Facts and clinical case study</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5116-836X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Васильева</surname><given-names>A. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vasileva</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Васильева Анна Владимировна, д.м.н., доцент, руководитель международного отдела, главный научный сотрудник отделения лечения пограничных психических расстройств и психотерапии, Национальный медицинский исследовательский центр психиатрии и неврологии имени В.М. Бехтерева; профессор кафедры психотерапии, медицинской психологии и сексологии, Северо-Западный государственный медицинский университет имени И.И. Мечникова</p><p>192019, Россия, Санкт-Петербург, ул. Бехтерева, д. 3,</p><p>191015, Россия, Санкт-Петербург, ул. Кирочная, д. 41</p></bio><bio xml:lang="en"><p>Anna V. Vasileva, Dr. Sci. (Med.), Associate Professor, Head of the International Department, Chief Researcher, Department of Borderline Mental Disorders and Psychotherapy, Bekhterev National Medical Research Centre for Psychiatry and Neurology; Professor of the Department of Psychotherapy, Medical Psychology, and Sexology, North-Western State Medical University named after</p><p>I.I. Mechnikov3, Bekhterev St., St Petersburg, 192019, </p><p>41, Kirochnaya St., St Petersburg, 191015</p></bio><email xlink:type="simple">annavdoc1@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр психиатрии и неврологии имени В.М. Бехтерева; &#13;
Северо-Западный государственный медицинский университет имени И.И. Мечникова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Bekhterev National Medical Research Centre for Psychiatry and Neurology; &#13;
North-Western State Medical University named after I.I. Mechnikov</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>11</day><month>01</month><year>2026</year></pub-date><volume>0</volume><issue>22</issue><fpage>114</fpage><lpage>122</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Васильева A.В., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Васильева A.В.</copyright-holder><copyright-holder xml:lang="en">Vasileva A.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/9727">https://www.med-sovet.pro/jour/article/view/9727</self-uri><abstract><p>Пограничное расстройство личности – диагноз, который существует в нашем профессиональном поле уже более 30 лет и, по данным различных эпидемиологических исследований, является гораздо более распространенным, чем шизофрения. Однако в отечественной медицине до сих пор остаются сложности с его своевременной выявляемостью и подбором терапии. С одной стороны, это связано с полиморфизмом симптоматики и высокой коморбидностью пограничного расстройства личности с тревожно-депрессивными расстройствами и злоупотреблением психоактивными веществами. С другой стороны, этот диагноз не имеет прямых аналогов в трудах классиков отечественной психиатрии. В настоящее время пограничное расстройство личности имеет самую большую базу доказательных исследований эффективного использования психотерапии среди других расстройств личности, открытым остается вопрос поиска эффективной психофармакотерапии. В рутинной практике большинство пациентов с пограничным расстройством личности получают медикаментозное лечение. В представленном случае описаны трудности поддержания рутинной деятельности, ставшие причиной декомпенсации пограничного расстройства личности. Представлена стратегия выбора лечения при отказе от психотерапии в соответствии с отечественными клиническими рекомендациями и индивидуальным профилем симптомов, таких как генерализованная тревога, раздражительность, субдепрессивное настроение, что определяет назначение анксиолитика с серотонинергическим и дофаминергическим действием препаратом выбора. Продемонстрирована положительная динамика состояния и возможность использования цифровых ассистентов как средства самопомощи. Анализ базы клинических случаев, подобных представленному в статье, может стать основой для разработки рекомендаций по психофармакотерапии пограничного расстройства личности в парадигме исследований в реальном мире, что позволит сократить разрыв между наукой и практикой.</p></abstract><trans-abstract xml:lang="en"><p>Borderline personality disorder is a diagnosis that exists in our professional field already more than 30 years and according to numerous epidemiological studies has higher incidence than schizophrenia. However in Russian healthcare we still have difficulties with its adequate diagnostic and treatment. It can be explained by the symptoms polymorphism of borderline personality disorder itself and it’s high comorbidity with anxiety depression and substance abuse, on the other hand this diagnosis doesn’t have any analogies in the works of Russian classical psychiatrists. Nowadays bod has the greatest evidence base of psychotherapy efficiency among personality disorders, the efficient psychoharmacotherapy is still a challenge for future study. In the routine practice the majority of borderline personality disorder patients gets psychopharmacotgerapy. In the described case study the difficulties to maintain routine activity made an impact for borderline personality disorder decompensation. The treatment choice has been made according to the Russian guidelines for diagnostic and treatment of personality disorders and individual symptoms profile: free floating anxiety irritability and subdepressive mood, it determined the prescription of anxyolitic with seritoninergic and dofaminergic mechanism of action as treatment choice. Significant improvement has been shown as well as the digital assistance use as self help tool. Case study base analysis as the one published in this article can be served as the source for the borderline personality disorder psychopharmacological treatment guidelines elaboration in the real world studies paradigm that can help to bridge the gap between research and practice.</p><p> </p></trans-abstract><kwd-group xml:lang="ru"><kwd>пограничное расстройство личности</kwd><kwd>коморбидность</kwd><kwd>тревога</kwd><kwd>депрессия</kwd><kwd>психотерапия</kwd><kwd>психофармакотерапия</kwd><kwd>буспирон</kwd></kwd-group><kwd-group xml:lang="en"><kwd>borderline personality disorder</kwd><kwd>comorbidity</kwd><kwd>anxiety</kwd><kwd>depression</kwd><kwd>psychotherapy</kwd><kwd>psychopharmacotherapy</kwd><kwd>buspirone</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Снедков ЕВ. Страсти по психопатии (продолжение обсуждения статьи В.Д. Менделевича). Неврологический вестник. 2017;(3):92–98. Режим доступа: https://journals.eco-vector.com/1027-4898/article/view/14096.</mixed-citation><mixed-citation xml:lang="en">Snedkov EV. Passion for psychopathy (continuation of discussion on V.D. Mendelevich’s paper). Neurology Bulletin. 2017;(3):92–98. (In Russ.) Available at: https://journals.eco-vector.com/1027-4898/article/view/14096.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Schneider K (ed.). Klinische Psychopathologie. Stuttgart: Georg Thieme Verlag KG; 2007. https://doi.org/10.1055/b-002-44928.</mixed-citation><mixed-citation xml:lang="en">Schneider K (ed.). Klinische Psychopathologie. Stuttgart: Georg Thieme Verlag KG; 2007. https://doi.org/10.1055/b-002-44928.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Пятницкий НЮ. Психопатии и психопатические реакции: концепция O. Bumke. Психиатрия. 2020;18(3):86–94. https://doi.org/10.30629/2618-6667-2020-18-3-86-94.</mixed-citation><mixed-citation xml:lang="en">Pyatnitskiy NYu. Psychopathies and Psychopathic Reactions: Concept of O. Bumke. Psychiatry (Moscow). 2020;18(3):86–94. (In Russ.) https://doi.org/10.30629/2618-6667-2020-18-3-86-94.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ганнушкин ПБ. Клиника психопатий, их статика, динамика, систематика. Н. Новгород: НГМД; 1998. 128 с.</mixed-citation><mixed-citation xml:lang="en">Ганнушкин ПБ. Клиника психопатий, их статика, динамика, систематика. Н. Новгород: НГМД; 1998. 128 с.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Менделевич ВД. Личностные расстройства (психопатии): сохранять ли в психиатрических классификациях и лечить ли антипсихотиками? (Ответ на статью Д.С. Данилова). Психиатрия и психофармакотерапия. 2017;19(3):57–60. Режим доступа: https://con-med.ru/magazines/psikhiatriya_i_psikhofarmakoterapiya_im_p_b_ganushkina/psikhiatriya_i_psikhofarmakoterapiya_im_p_b_ganushkina-03-2017/lichnostnye_rasstroystva_psikhopatii_sokhranyat_li_v_psikhiatricheskikh_klassifikatsiyakh_i_lechit_l/.</mixed-citation><mixed-citation xml:lang="en">Mendelevich VD. Personality disorders (psychopathy): whether to keep psychiatric classifications and whether to use antipsychotics for treatment? (Response to the D.S. Danilov’s article). Psikhiatriya i Psikhofarmakoterapiya. 2017;19(3):57–60. (In Russ.) Available at: https://con-med.ru/magazines/psikhiatriya_i_psikhofarmakoterapiya_im_p_b_ganushkina/psikhiatriya_i_psikhofarmakoterapiya_im_p_b_ganushkina-03-2017/lichnostnye_rasstroystva_psikhopatii_sokhranyat_li_v_psikhiatricheskikh_klassifikatsiyakh_i_lechit_l/.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kernberg OF, Clarkin JF. The Inventory of Personality Organization. New York Hospital-Cornell Medical Center; 1995. https://doi.org/10.1037/t01122-000.</mixed-citation><mixed-citation xml:lang="en">Kernberg OF, Clarkin JF. The Inventory of Personality Organization. New York Hospital-Cornell Medical Center; 1995. https://doi.org/10.1037/t01122-000.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Васильева АВ, Караваева ТА, Незнанов НГ (ред.). Психотерапия: национальное руководство. Москва: ГЭОТАР-Медиа; 2023. 992 с.</mixed-citation><mixed-citation xml:lang="en">Васильева АВ, Караваева ТА, Незнанов НГ (ред.). Психотерапия: национальное руководство. Москва: ГЭОТАР-Медиа; 2023. 992 с.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Bohus M, Stoffers-Winterling J, Sharp C, Krause-Utz A, Schmahl C, Lieb K. Borderline personality disorder. Lancet. 202;398(10310):1528–1540. https://doi.org/10.1016/S0140-6736(21)00476-1.</mixed-citation><mixed-citation xml:lang="en">Bohus M, Stoffers-Winterling J, Sharp C, Krause-Utz A, Schmahl C, Lieb K. Borderline personality disorder. Lancet. 202;398(10310):1528–1540. https://doi.org/10.1016/S0140-6736(21)00476-1.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Петрова НН, Чарная ДИ, Чумаков ЕМ. Пограничное расстройство личности: к вопросу о диагнозе. Доктор.Ру. 2022;21(8):66–71. https://doi.org/10.31550/1727-2378-2022-21-8-66-71.</mixed-citation><mixed-citation xml:lang="en">Petrova NN, Charnaya DI, Chumakov EM. Borderline Personality Disorder: Diagnosis. Doctor.Ru. 2022;21(8):66–71. (In Russ.) https://doi.org/10.31550/1727-2378-2022-21-8-66-71.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">McMahon K, Hoertel N, Peyre H, Blanco C, Fang C, Limosin F. Age differences in DSM-IV borderline personality disorder symptom expression: Results from a national study using item response theory (IRT). J Psychiatr Res. 2019;110:16–23. https://doi.org/10.1016/j.jpsychires.2018.12.019.</mixed-citation><mixed-citation xml:lang="en">McMahon K, Hoertel N, Peyre H, Blanco C, Fang C, Limosin F. Age differences in DSM-IV borderline personality disorder symptom expression: Results from a national study using item response theory (IRT). J Psychiatr Res. 2019;110:16–23. https://doi.org/10.1016/j.jpsychires.2018.12.019.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Corniquel MB, Koenigsberg HW, Likhtik E. Toward an animal model of borderline personality disorder. Psychopharmacology. 2019;236(8):2485–2500. https://doi.org/10.1007/s00213-019-05289-x.</mixed-citation><mixed-citation xml:lang="en">Corniquel MB, Koenigsberg HW, Likhtik E. Toward an animal model of borderline personality disorder. Psychopharmacology. 2019;236(8):2485–2500. https://doi.org/10.1007/s00213-019-05289-x.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Kuhlman KR. Pitfalls and potential: Translating the two-hit model of early life stress from pre-clinical non-human experiments to human samples. Brain Behav Immun Health. 2023;35:100711. https://doi.org/10.1016/j.bbih.2023.100711.</mixed-citation><mixed-citation xml:lang="en">Kuhlman KR. Pitfalls and potential: Translating the two-hit model of early life stress from pre-clinical non-human experiments to human samples. Brain Behav Immun Health. 2023;35:100711. https://doi.org/10.1016/j.bbih.2023.100711.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Bower JE, Kuhlman KR. Psychoneuroimmunology: An Introduction to Immuneto-Brain Communication and Its Implications for Clinical Psychology. Annu Rev Clin Psychol. 2023;19:331–359. https://doi.org/10.1146/annurevclinpsy-080621-045153.</mixed-citation><mixed-citation xml:lang="en">Bower JE, Kuhlman KR. Psychoneuroimmunology: An Introduction to Immuneto-Brain Communication and Its Implications for Clinical Psychology. Annu Rev Clin Psychol. 2023;19:331–359. https://doi.org/10.1146/annurevclinpsy-080621-045153.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Pariante CM. Psychoneuroimmunology or immunopsychiatry? Lancet Psychiatry. 2015;2(3):197–199. https://doi.org/10.1016/S2215-0366(15)00042-5.</mixed-citation><mixed-citation xml:lang="en">Pariante CM. Psychoneuroimmunology or immunopsychiatry? Lancet Psychiatry. 2015;2(3):197–199. https://doi.org/10.1016/S2215-0366(15)00042-5.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Fitzpatrick S, Liebman RE, Monson CM. The borderline interpersonal-affective systems (BIAS) model: Extending understanding of the interpersonal context of borderline personality disorder. Clin Psychol Rev. 2021;84:101983. https://doi.org/10.1016/j.cpr.2021.101983.</mixed-citation><mixed-citation xml:lang="en">Fitzpatrick S, Liebman RE, Monson CM. The borderline interpersonal-affective systems (BIAS) model: Extending understanding of the interpersonal context of borderline personality disorder. Clin Psychol Rev. 2021;84:101983. https://doi.org/10.1016/j.cpr.2021.101983.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Kazdin AE. Single-case experimental designs. Evaluating interventions in research and clinical practice. Behav Res Ther. 2019;117:3–17. https://doi.org/10.1016/j.brat.2018.11.015.</mixed-citation><mixed-citation xml:lang="en">Kazdin AE. Single-case experimental designs. Evaluating interventions in research and clinical practice. Behav Res Ther. 2019;117:3–17. https://doi.org/10.1016/j.brat.2018.11.015.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Persons JB, Boswell JF. Single case and idiographic research: Introduction to the special issue. Behav Res Ther. 2019;117:1–2. https://doi.org/10.1016/j.brat.2019.03.007.</mixed-citation><mixed-citation xml:lang="en">Persons JB, Boswell JF. Single case and idiographic research: Introduction to the special issue. Behav Res Ther. 2019;117:1–2. https://doi.org/10.1016/j.brat.2019.03.007.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Прусова ТИ, Васильева АВ, Караваева ТА. Описание случая: депрессивное расстройство и невыявленное своевременно коморбидное пограничное расстройство личности. Современная терапия психических расстройств. 2025;(1):67–74. https://doi.org/10.48612/psyph/2n75-f9fa-ur2h.</mixed-citation><mixed-citation xml:lang="en">Prusova TI, Vasileva AV, Karavaeva TA. Clinical Case: Depressive Disorder and Undiagnosed Comorbid Borderline Personality Disorder. Current Therapy of Mental Disorders. 2025;(1):67–74. (In Russ.) https://doi.org/10.48612/psyph/2n75-f9fa-ur2h.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Быков ЮВ, Беккер РА. Буспирон в практике врача-психиатра: только ли анксиолитик? Психиатрия и психофармакотерапия. 2017;19(5):32–52. Режим доступа: https://www.elibrary.ru/zvytvj.</mixed-citation><mixed-citation xml:lang="en">Bykov YuV, Becker RA. Buspiron in psychiatric practice: is it only an anxiolytic? Psikhiatriya i Psikhofarmakoterapiya. 2017;19(5):32–52. (In Russ.) Available at: https://www.elibrary.ru/zvytvj.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Howland RH. Buspirone: Back to the Future. J Psychosoc Nurs Ment Health Serv. 2015;53(11):21–24. https://doi.org/10.3928/02793695-20151022-01.</mixed-citation><mixed-citation xml:lang="en">Howland RH. Buspirone: Back to the Future. J Psychosoc Nurs Ment Health Serv. 2015;53(11):21–24. https://doi.org/10.3928/02793695-20151022-01.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Bandelow B, Allgulander C, Baldwin DS, Costa DLDC, Denys D, Dilbaz N et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part I: Anxiety disorders. World J Biol Psychiatry. 2023;24(2):79–117. https://doi.org/10.1080/15622975.2022.2086295.</mixed-citation><mixed-citation xml:lang="en">Bandelow B, Allgulander C, Baldwin DS, Costa DLDC, Denys D, Dilbaz N et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part I: Anxiety disorders. World J Biol Psychiatry. 2023;24(2):79–117. https://doi.org/10.1080/15622975.2022.2086295.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Kim JK, Han SK, Joo MK, Kim DH. Buspirone alleviates anxiety, depression, and colitis; and modulates gut microbiota in mice. Sci Rep. 2021;11(1):6094. https://doi.org/10.1038/s41598-021-85681-w.</mixed-citation><mixed-citation xml:lang="en">Kim JK, Han SK, Joo MK, Kim DH. Buspirone alleviates anxiety, depression, and colitis; and modulates gut microbiota in mice. Sci Rep. 2021;11(1):6094. https://doi.org/10.1038/s41598-021-85681-w.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Malikowska-Racia N, Popik P, Sałat K. Behavioral effects of buspirone in a mouse model of posttraumatic stress disorder. Behav Brain Res. 2020;381:112380. https://doi.org/10.1016/j.bbr.2019.112380.</mixed-citation><mixed-citation xml:lang="en">Malikowska-Racia N, Popik P, Sałat K. Behavioral effects of buspirone in a mouse model of posttraumatic stress disorder. Behav Brain Res. 2020;381:112380. https://doi.org/10.1016/j.bbr.2019.112380.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Duffy JD, Malloy PF. Efficacy of buspirone in the treatment of posttraumatic stress disorder: an open trial. Ann Clin Psychiatry. 1994;6(1):33–37. https://doi.org/10.3109/10401239409148837.</mixed-citation><mixed-citation xml:lang="en">Duffy JD, Malloy PF. Efficacy of buspirone in the treatment of posttraumatic stress disorder: an open trial. Ann Clin Psychiatry. 1994;6(1):33–37. https://doi.org/10.3109/10401239409148837.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Stoffers JM, Völlm BA, Rücker G, Timmer A, Huband N, Lieb K. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev. 2012;(8):CD005652. https://doi.org/10.1002/14651858.CD005652.pub2.</mixed-citation><mixed-citation xml:lang="en">Stoffers JM, Völlm BA, Rücker G, Timmer A, Huband N, Lieb K. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev. 2012;(8):CD005652. https://doi.org/10.1002/14651858.CD005652.pub2.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Stone MH. Borderline Personality Disorder: Clinical Guidelines for Treatment. Psychodyn Psychiatry. 2022;50(1):45–63. https://doi.org/10.1521/pdps.2022.50.1.45.</mixed-citation><mixed-citation xml:lang="en">Stone MH. Borderline Personality Disorder: Clinical Guidelines for Treatment. Psychodyn Psychiatry. 2022;50(1):45–63. https://doi.org/10.1521/pdps.2022.50.1.45.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Stoffers-Winterling J, Völlm B, Lieb K. Is pharmacotherapy useful for treating personality disorders? Expert Opin Pharmacother. 2021;22(4):393–395. https://doi.org/10.1080/14656566.2021.1873277.</mixed-citation><mixed-citation xml:lang="en">Stoffers-Winterling J, Völlm B, Lieb K. Is pharmacotherapy useful for treating personality disorders? Expert Opin Pharmacother. 2021;22(4):393–395. https://doi.org/10.1080/14656566.2021.1873277.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Livesley WJ, Jang KL, Jackson DN, Vernon PA. Genetic and environmental contributions to dimensions of personality disorder. Am J Psychiatry. 1993;150(12):1826–1831. https://doi.org/10.1176/ajp.150.12.1826.</mixed-citation><mixed-citation xml:lang="en">Livesley WJ, Jang KL, Jackson DN, Vernon PA. Genetic and environmental contributions to dimensions of personality disorder. Am J Psychiatry. 1993;150(12):1826–1831. https://doi.org/10.1176/ajp.150.12.1826.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Siever LJ, Davis KL. A psychobiological perspective on the personality disorders. Am J Psychiatry. 1991;148(12):1647–1658. https://doi.org/10.1176/ajp.148.12.1647.</mixed-citation><mixed-citation xml:lang="en">Siever LJ, Davis KL. A psychobiological perspective on the personality disorders. Am J Psychiatry. 1991;148(12):1647–1658. https://doi.org/10.1176/ajp.148.12.1647.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Keuroghlian AS, Frankenburg FR, Zanarini MC. The relationship of chronic medical illnesses, poor health-related lifestyle choices, and health care utilization to recovery status in borderline patients over a decade of prospective follow-up. J Psychiatr Res. 2013;47(10):1499–1506. https://doi.org/10.1016/j.jpsychires.2013.06.012.</mixed-citation><mixed-citation xml:lang="en">Keuroghlian AS, Frankenburg FR, Zanarini MC. The relationship of chronic medical illnesses, poor health-related lifestyle choices, and health care utilization to recovery status in borderline patients over a decade of prospective follow-up. J Psychiatr Res. 2013;47(10):1499–1506. https://doi.org/10.1016/j.jpsychires.2013.06.012.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Madan A, Oldham JM, Gonzalez S, Fowler JC. Reducing Adverse Polypharmacy in Patients With Borderline Personality Disorder: An Empirical Case Study. Prim Care Companion CNS Disord. 2015;17(4):10.4088/PCC.14m01760. https://doi.org/10.4088/PCC.14m01760.</mixed-citation><mixed-citation xml:lang="en">Madan A, Oldham JM, Gonzalez S, Fowler JC. Reducing Adverse Polypharmacy in Patients With Borderline Personality Disorder: An Empirical Case Study. Prim Care Companion CNS Disord. 2015;17(4):10.4088/PCC.14m01760. https://doi.org/10.4088/PCC.14m01760.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Шишковская ТИ, Леонова АВ, Петрова НН. Расстройства личности: от исторических аспектов к современным представлениям. Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева. https://doi.org/10.31363/2313-7053-2025-4-1084.</mixed-citation><mixed-citation xml:lang="en">Shishkovskaia TI, Leonova AV, Petrova NN. Personality disorders: from historical aspects to contemporary views. V.M. Bekhterev Review of Psychiatry and Medical Psychology. (In Russ.) https://doi.org/10.31363/2313-7053-2025-4-1084.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Stoffers J, Völlm BA, Rücker G, Timmer A, Huband N, Lieb K. Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev. 2010;(6):CD005653. https://doi.org/10.1002/14651858.CD005653.pub2.</mixed-citation><mixed-citation xml:lang="en">Stoffers J, Völlm BA, Rücker G, Timmer A, Huband N, Lieb K. Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev. 2010;(6):CD005653. https://doi.org/10.1002/14651858.CD005653.pub2.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Pascual JC, Arias L, Soler J. Pharmacological Management of Borderline Personality Disorder and Common Comorbidities. CNS Drugs. 2023;37(6):489–497. https://doi.org/10.1007/s40263-023-01015-6.</mixed-citation><mixed-citation xml:lang="en">Pascual JC, Arias L, Soler J. Pharmacological Management of Borderline Personality Disorder and Common Comorbidities. CNS Drugs. 2023;37(6):489–497. https://doi.org/10.1007/s40263-023-01015-6.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R et al. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Borderline Personality Disorder. Am J Psychiatry. 2024;181(11):1024–1028. https://doi.org/10.1176/appi.ajp.24181010.</mixed-citation><mixed-citation xml:lang="en">Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R et al. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Borderline Personality Disorder. Am J Psychiatry. 2024;181(11):1024–1028. https://doi.org/10.1176/appi.ajp.24181010.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">National Institute for Health and Clinical Excellence. Personality Disorders: Borderline and Antisocial. 2015. 31 p. Available at: https://www.nice.org.uk/guidance/qs88.</mixed-citation><mixed-citation xml:lang="en">National Institute for Health and Clinical Excellence. Personality Disorders: Borderline and Antisocial. 2015. 31 p. Available at: https://www.nice.org.uk/guidance/qs88.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">National Health and Medical Research Council. Clinical Practice Guideline for the Management of Borderline. Personality Disorder. Melbourne: National Health and Medical Research Council; 2012. 182 p. Available at: https://bpdfoundation.org.au/images/mh25_borderline_personality_guideline.pdf.</mixed-citation><mixed-citation xml:lang="en">National Health and Medical Research Council. Clinical Practice Guideline for the Management of Borderline. Personality Disorder. Melbourne: National Health and Medical Research Council; 2012. 182 p. Available at: https://bpdfoundation.org.au/images/mh25_borderline_personality_guideline.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Караваева ТА, Васильева АВ, Идрисов КА, Ковлен ДВ, Незнанов НГ, Пономаренко ГН и др. Посттравматическое стрессовое расстройство: клинические рекомендации. М.; 2023. 200 с. Режим доступа: https://cr.minzdrav.gov.ru/preview-cr/753_1.</mixed-citation><mixed-citation xml:lang="en">Караваева ТА, Васильева АВ, Идрисов КА, Ковлен ДВ, Незнанов НГ, Пономаренко ГН и др. Посттравматическое стрессовое расстройство: клинические рекомендации. М.; 2023. 200 с. Режим доступа: https://cr.minzdrav.gov.ru/preview-cr/753_1.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Hu H, Phan N, Geller J, Iezzi S, Vo H, Dou D, Chun SA. An Ensemble Deep Learning Model for Drug Abuse Detection in Sparse Twitter-Sphere. Stud Health Technol Inform. 2019;264:163–167. https://doi.org/10.3233/SHTI190204.</mixed-citation><mixed-citation xml:lang="en">Hu H, Phan N, Geller J, Iezzi S, Vo H, Dou D, Chun SA. An Ensemble Deep Learning Model for Drug Abuse Detection in Sparse Twitter-Sphere. Stud Health Technol Inform. 2019;264:163–167. https://doi.org/10.3233/SHTI190204.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">De Anta L, Alvarez-Mon MÁ, Pereira-Sanchez V, Donat-Vargas CC, Lara-Abelenda FJ, Arrieta M et al. Assessment of beliefs and attitudes towards benzodiazepines using machine learning based on social media posts: an observational study. BMC Psychiatry. 2024;24(1):659. https://doi.org/10.1186/s12888-024-06111-5.</mixed-citation><mixed-citation xml:lang="en">De Anta L, Alvarez-Mon MÁ, Pereira-Sanchez V, Donat-Vargas CC, Lara-Abelenda FJ, Arrieta M et al. Assessment of beliefs and attitudes towards benzodiazepines using machine learning based on social media posts: an observational study. BMC Psychiatry. 2024;24(1):659. https://doi.org/10.1186/s12888-024-06111-5.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Mullin A, Scott M, Vaccaro G, Floresta G, Arillotta D, Catalani V et al. Benzodiazepine Boom: Tracking Etizolam, Pyrazolam, and Flubromazepam from Pre-UK Psychoactive Act 2016 to Present Using Analytical and Social Listening Techniques. Pharmacy. 2024;12(1):13. https://doi.org/10.3390/pharmacy12010013.</mixed-citation><mixed-citation xml:lang="en">Mullin A, Scott M, Vaccaro G, Floresta G, Arillotta D, Catalani V et al. Benzodiazepine Boom: Tracking Etizolam, Pyrazolam, and Flubromazepam from Pre-UK Psychoactive Act 2016 to Present Using Analytical and Social Listening Techniques. Pharmacy. 2024;12(1):13. https://doi.org/10.3390/pharmacy12010013.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Stoffers-Winterling J, Storebø OJ, Lieb K. Pharmacotherapy for Borderline Personality Disorder: an Update of Published, Unpublished and Ongoing Studies. Curr Psychiatry Rep. 2020;22(8):37. https://doi.org/10.1007/s11920-020-01164-1.</mixed-citation><mixed-citation xml:lang="en">Stoffers-Winterling J, Storebø OJ, Lieb K. Pharmacotherapy for Borderline Personality Disorder: an Update of Published, Unpublished and Ongoing Studies. Curr Psychiatry Rep. 2020;22(8):37. https://doi.org/10.1007/s11920-020-01164-1.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
